Daniel R. Kuritzkes - Concepedia

Author

Daniel R. Kuritzkes

Also Known As

Babafemi Taiwo, Castro, Jose, Currier, Judith S., D Kuritzkes, D R Kuritzkes, D. Kuritzkes, D. R. Kuritzkes, D.R. Kuritzkes, DANIEL R. KURITZKES, Daniel Kuritzkes

525

Publications

30.6K

Citations

H-Index

205

Concepts

All Affiliations

Harvard University Brigham and Women's Hospital University of Colorado Health Massachusetts General Hospital University of California, San Francisco

About

Daniel R. Kuritzkes is an author at Harvard University specializing in medicine, hiv, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	106	10.6K
2	Public Health	14	17	2.9K
3	Engineering	12	12	1.1K
4	Health Sciences	11	11	511
5	Natural Sciences	5	5	392

Daniel R. Kuritzkes

284

Publications

25.2K

Citations

H-Index

Page 1

	Year	Citations
SARS-CoV-2 viral load is associated with increased disease severity and mortality Jesse Fajnzylber, James Regan, Kendyll Coxen, Nature Communications Plasma ViremiaSars-cov-2 Viral LoadViral PersistenceViral DiagnosticsCovid-19 Pandemic	2020	957
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update Diane Bennett, Ricardo Camacho, Dan Oţelea, PLoS ONE Protease PositionsTransmitted Hiv-1 Drug-resistanceDrug Resistance MutationsHiv-1 TreatmentTreatment And Prevention	2009	951
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America Jacob Lalezari, Keith Henry, Mary O’Hearn, New England Journal of Medicine	2003	909
Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel Martin S. Hirsch, Huldrych F. Günthard, Jonathan Schapiro, Clinical Infectious Diseases Sexual HealthTreatment And PreventionHuman RetrovirusAntiviral TherapyResistance Mutation (Virology)	2008	573
Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter Joseph J. Eron, Sharon L. Benoit, Joseph G. Jemsek, New England Journal of Medicine	1995	538
Aging and Infectious Diseases: Workshop on HIV Infection and Aging: What Is Known and Future Research Directions Rita B. Effros, Courtney V. Fletcher, Kelly A. Gebo, Clinical Infectious Diseases AgingImmunologyBiogerontologyHuman Immunodeficiency VirusEpidemiology Of Aging	2008	534
Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection Roy M. Gulick, Heather J. Ribaudo, Cecilia M. Shikuma, New England Journal of Medicine	2004	526
Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel Martin Hirsch, Françoise Brun‐Vézinet, Bonaventura Clotet, Clinical Infectious Diseases Primary ImmunodeficiencyType 1Sexual HealthHiv/aids CounsellingAdults Infected	2003	516
Immunologic Responses Associated with 12 Weeks of Combination Antiretroviral Therapy Consisting of Zidovudine, Lamivudine, and Ritonavir: Results of AIDS Clinical Trials Group Protocol 315 Michael M. Lederman, Elizabeth Connick, Alan Landay, The Journal of Infectious Diseases Immunologic Responses AssociatedImmune ActivationImmunologyAntiviral DrugHuman Immunodeficiency Virus	1998	427
Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation Timothy J. Henrich, Emily Hanhauser, Francisco M. Marty, Annals of Internal Medicine	2014	398

Page 1